Arena Pharmaceuticals — Investor Presentation (January 2020)
44 slides from Arena Pharmaceuticals's investor presentation, Jan 10, 2020
Slide 1: Building a vibrant enterprise to deliver transformational medicines
Building a vibrant enterprise to deliver transformational medicines January 2020 • Nasdaq: ARNA Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including t
Slide 3: Value Creation Over the Past 3.5 Years
Value Creation Over the Past 3.5 Years *Cash, cash equivalents and investments as of 12/31/19 2016 Reset initiated Begin recruitment of new management team Spin-out discovery research (Beacon Discovery) Divested BELVIQ (Eisai) Initiated clean up of financial health ~$1.1 B* Cash 2018 Etrasimod Posit
Slide 4: 2020-21 Data Catalysts Expected
2020-21 Data Catalysts Expected Pipeline: 4 Clinical stage assets** 8 Diseases 2 Ph 3 6 Ph 2 Today Etrasimod: Potential Best-in-Class UC Ph 3 CD Ph 2/3 AD Ph 2b Olorinab: Potential First-in-Class IBS-C and IBS-D Pain Ph 2b APD418: Potential First-in-Class DHF Ph 1 Ralinepag Partnership* Architecting
Slide 5: Deep Pipeline with Therapeutic Focus
Deep Pipeline with Therapeutic Focus Internal Programs: Pre-clin. Phase 1 Phase 2 Phase 3 Etrasimod GI ELEVATE UC 52 ELEVATE UC 12 Crohn’s Disease (CD) Eosinophilic Esophagitis (EoE) Derm ADVISE (Atopic Dermatitis) Alopecia Areata (AA) Olorinab GI CAPTIVATE (Pain with IBS) Pain with IBD APD418 CV De
Slide 6: Expect Eight Ph 2 & Ph 3 Data Readouts in 2020-21
Expect Eight Ph 2 & Ph 3 Data Readouts in 2020-21 1 New IND Per Year Etrasimod UC NDA Submission Olorinab CAPTIVATE (IBS Pain) Ph 2b Data Etrasimod ADVISE (AD) Ph 2b Data Etrasimod CD Ph 3 Data Etrasimod Complete ELEVATE UC 52 Enrollment APD418 Ph 1 Data 2020 2021 2022 New IND(s) New IND(s) New IND(
Slide 7: Arena Neuroscience – Microglial Neuroinflammation Platform
Arena Neuroscience – Microglial Neuroinflammation Platform Scientific Rationale: Programs: Sentinel microglia encounter aberrant proteins like: mSOD (ALS) α-Synuclein (Parkinson’s Disease) Aβ (Alzheimer's Disease) resulting in activated microglia These proteins lead to exaggerated neuroinflammatory
Slide 8: Expanded Multi-target GPCR Relationship with Beacon Discovery
Expanded Multi-target GPCR Relationship with Beacon Discovery Novel Immune and Inflammatory Research: Early research program with Beacon Discovery to discover and develop novel compounds with multiple GPCR targets/MOAs Strengthens Arena’s early-stage GI portfolio Preclinically validated targets usin
Slide 9: Etrasimod: Investigational, Oral, Next Generation S1P Receptor Modulator
Etrasimod Investigational, Oral, Next Generation, S1P Receptor Modulator with Potential for Optimized Activity Being Evaluated for Multiple Immune-Mediated Inflammatory Diseases (IMID), Targeting ~$48B Market with Current Indications January 2020 •
Slide 10: Potential Best-in-Class S1P Receptor Modulator with Broad Applicability
Etrasimod Potential Best-in-Class S1P Receptor Modulator with Broad Applicability Source: 1. Arena Quantitative Market Research, March 2018.; 2. Dahlhamer JM, et al. MMWR Morb Mortal Wkly Rep 2016;65:1166–1169.; 3. UC & CD Disease Landscape & Forecast Reports. DRG. 2018 January 2020 • Receptor Pharm
Slide 11: Designed to Offer Control with Faster Offset & Onset
Etrasimod Designed to Offer Control with Faster Offset & Onset Source: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-9962- ADP334 P1 Data on File. 3- ADP334 P1 Data on File; *Active metabolite; *After dose escalation of ozanimod (0.3 mg/d on days 1–3; 0.6 mg/d on days 4 and 5; 1 mg/d on days 6 and
Slide 12: in Gastrointestinal Conditions
Etrasimod in Gastrointestinal Conditions Ulcerative Colitis (UC), Crohn’s Disease (CD) & Eosinophilic Esophagitis (EoE) January 2020 •
Slide 13: Potential Opportunity to Create a New Standard of Care Across GI Conditions
Etrasimod Has the Potential Opportunity to Create a New Standard of Care Across a Spectrum of GI Conditions Adult patient's with moderately to severely active disease who have had inadequate response, lost response or are intolerant to either conventional therapy, biologic agents or JAKi therapy Ulc
Slide 14: Potential Best-in-Disease S1P Receptor Modulator with Broad Potential Applicability
Etrasimod Potential Best-in-Disease S1P Receptor Modulator with Broad Potential Applicability Source: 1. Arena Quantitative Market Research, March 2018.; 2. Dahlhamer JM, et al. MMWR Morb Mortal Wkly Rep 2016;65:1166–1169.; 3. UC & CD Disease Landscape & Forecast Reports. DRG. 2018 60-80% $24+B Mark
Slide 15: Efficacy in UC (4-Domain)
Etrasimod Efficacy in UC (4-Domain) Source: Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists.. Sources: Ozanimod: Sandborn, et al. NEJM 2016; Xeljanz: Sandborn, et al.
Slide 16: Demonstrated Strong Efficacy Across Multiple Mayo Scores
Etrasimod Demonstrated Strong Efficacy Across Multiple Mayo Scores and Rapid Improvement in Clinical Symptoms 4-Domain OASIS1 3-Domain OASIS1 Patients with TMCS ≤ 2 points and No Subscore > 1 point N=54 N=50 Clinical Remission defined as RB= 0; Endoscopic Improvement = 0,1; SF= 0,1 (per FDA draft gu
Slide 17: Open-Label Extension of Phase 2 OASIS Study
Open-Label Extension of Phase 2 OASIS Study Etrasimod demonstrated sustained clinical activity at Week 46 „ Clinical Remission 77% Clinical Response Endoscopic Improvement 93% 75% January 2020 • Source: OLE of OASIS Ph 2, data on file
Slide 18: Phase 2 Safety Results
Phase 2 Safety Results Adverse events were predominantly mild to moderate No serious adverse events (SAEs) at the 2 mg dose Impact on HR and AV conduction was low throughout the study with no discontinuations related to bradycardia or AV block. No SAEs related to HR changes or AV block No cases of s
Slide 19: Market Research Supports Etrasimod as Potential Market Leader in IBD
Market Research Supports Etrasimod as Potential Market Leader in IBD Source: Arena data on file. Oral Market Increasing (Estimated Future Preference) S1P vs. JAK (Estimated Preference) Etrasimod vs. Ozanimod (Estimated Future Preference) Mod/Severe Patients Not Receiving Biologics January 2020 •
Slide 20: Global Phase 3 Program in UC
Etrasimod Global Phase 3 Program in UC Moderately to Severely Active UC 52-Week Treat-Through Adults Biologics / JAK inhibitor ~50% naïve / 50% exposed Endpoints Primary Endpoint Trial 1: Week 12, week 52 clinical remission (modified MCS) Primary Endpoint Trial 2: Week 12 clinical remission (modifie
Slide 21: Phase 2/3 Program in CD
Etrasimod Phase 2/3 Program in CD CULTIVATE Ph 2 dose-ranging study testing safety and efficacy of etrasimod 2 mg and 3 mg compared to placebo in ~225 patients Primary efficacy endpoint will be endoscopic response at Week 14 Evaluating at a variety of scales of Crohn’s disease activity, including ab
Slide 22: Aims to Address Unmet Need in Eosinophilic Esophagitis (EoE)
Etrasimod Aims to Address Unmet Need in Eosinophilic Esophagitis (EoE) Source: 1. Aria Exp Rev Gastroenterol Hepatol. 2019;13:99-117.; 2. Gonsalves Cli Rev Allergy Immunol 2019; doi: 10.1007/s12016-019-08732-1 IMID = immune-mediated inflammatory disease Strong Preference for Oral non-steroid Treatme
Slide 23: EoE - Multiple Infiltrating Cells Beyond Eosinophils and Mast Cells
EoE - Multiple Infiltrating Cells Beyond Eosinophils and Mast Cells 1- Lucendo et al Am J Surg Pathol. 2001;31:598-606. Mast Cells Dendritic Cells (DC) IgE+ B cells Healthy EoE Eosinophils 0 62.58 Total T cells 12.37 83.64 CD4 T cells 4.61 26.66 CD8 T cells 11.06 79.84 B cells 0 2.48 DC 5.49 8.49 Ma
Slide 24: Preclinical Evidence Supporting EoE Investigation
Etrasimod Preclinical Evidence Supporting EoE Investigation Veh = vehicle, Dex = dexamethasone, mpk = mg/kg Sources: 1. Aria Exp Rev Gastroenterol Hepatol. 2019;13:99-117.; 2. Gonsalves Cli Rev Allergy Immunol 2019; doi: 10.1007/s12016-019-08732-1.; 3. Al Shamma et al. J Pharmacol Exp Ther 369:311-3
Slide 25: in Dermatologic Conditions
Etrasimod in Dermatologic Conditions Atopic Dermatitis (AD) Alopecia Areata (AA) January 2020 •
Slide 26: Aims to Address Unmet Need in Atopic Dermatitis
Etrasimod Aims to Address Unmet Need in Atopic Dermatitis Source: 1. Silverberg, JI. Dermatol Clin. 2017 Jul;35(3):283-289.; 2. Barbarot S, et al. Allergy. 2018 Jun;73(6):1284-1293.; 3. Egeberg A, et al. J Am Acad Dermatol. 2017 Jan;76(1):98-105.; 4. Atopic Dermatitis/Atopic Eczema. Disease Landscap
Slide 27: Preclinical Evidence Supporting AD Investigation
Etrasimod Preclinical Evidence Supporting AD Investigation Source: 1. Crosby et al. FITC induced contact-hypersensitivity dermatitis model, ESDR 2019 Bordeaux, France 2. Crosby et al. S1P1 modulator mouse asthma model AAI 2019, San Diego, CA 3. Arena data on file, Bleomycin-induced skin fibrosis mod
Slide 28: Early Clinical Result in Dermatologic Conditions
Etrasimod Early Clinical Result in Dermatologic Conditions Baseline Image Initial Measurement (7/5/17) Initial Area 4.668 CmSq Current Area 1.520 CmSq Image Date of Assessment (9/27/17) Percent Area Change -67.44% Length 2.18cm January 2020 •
Slide 29: Ph 2b Trial Evaluating Atopic Dermatitis
Etrasimod Ph 2b Trial Evaluating Atopic Dermatitis A Phase 2 Placebo-Controlled, Dose Finding Trial to Assess the Safety and Efficacy of Etrasimod in Subjects with Moderate-to-Severe AD Primary Endpoint Percent change in Eczema Area and Severity Index (EASI) from baseline to week 12 Study Detail Mal
Slide 30: Aims to Address Unmet Need in Alopecia Areata
Etrasimod Aims to Address Unmet Need in Alopecia Areata Sources: 1. Gilhar et al. NEJM 2012; 366:1515-25 2. Harvard Medical School. Alopecia Areata. Published: 01/2019; 3. Lee S., Lee H, et al. Comorbidities in alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:466-7
Slide 31: Disease Pathology Alopecia Areata
Disease Pathology Alopecia Areata1,2 Caused by a collapse in immune privilege in hair follicle bulb CD4+ and CD8+ T cells infiltrate the hair bulb during anagen phase of the hair growth cycle—“like a swarm of bees” Inflammation alters normal hair growth cycle and causes hair to fall out However, hai
Slide 32: Preclinical Evidence Supporting AA Investigation
Etrasimod Preclinical Evidence Supporting AA Investigation Is/Be: Isthmus/Bulge, Sbu: Suprabulbar area, Bu: Bulb, IC: Immune Cell Sources: 1. Gilhar et al. NEJM 2012; 366:1515-25 2. Peyrin-Biroulet et al. ECCO 2018, Vienna, Austria 3. Arena data on file (mouse dermatitis model), 4. Arena data on fil
Slide 33: Olorinab: Selective CB2 Agonist for Gastrointestinal Pain
Olorinab Peripherally Acting, Highly–Selective, Full-Agonist to Cannabinoid Receptor 2 (CB2) for Gastrointestinal Pain January 2020 •
Slide 34: Olorinab Aims to Address Unmet Need in Multiple Areas of Gut Pain
Olorinab Aims to Address Unmet Need in Multiple Areas of Gut Pain Sources: 1. DRG: IBS Report (2015); 2. The Facts About IBDs. Crohn’s & Colitis Foundation of America. 2014.; 3. Drossman DA, et al. J Clin Gastroenterol. 2009 Jul; 43(6): 541–550.; 4. Adelphi 2017.; 5. Hacker B, et al. P216. Presented
Slide 35: Olorinab Reduced Firing Rate of Colonic Pain Fibers
Olorinab Reduced Firing Rate of Colonic Pain Fibers in IBD and IBS-like models 1. Castro J, et al. Poster presented at: Digestive Disease Week; May 18-21, 2019; San Diego, CA. 2. Lindstrom B, et al. Poster presented at: 2019 Crohn’s & Colitis Congress; February 7-9, 2019; Las Vegas, NV. IBS-Like Col
Slide 36: Shared Mechanisms in IBS and IBD Pain
Shared Mechanisms in IBS and IBD Pain Sources: 1. Barbara et al., (2014) Curr Opin Gastroenterol 30:352-358; 2. Cremon et al., (2017) Alimentary Pharmacology and Therapeutics 45:909-922; 3. Dr. Lin Chang, unpublished data; 4. Spiller and Major (2016), Nat Rev Gastroenterol Hepatol 13(10):613-21; 5.
Slide 37: Strong Signal in Average Abdominal Pain Score and Responder Analysis
Strong Signal in Average Abdominal Pain Score (AAPS) and Responder Analysis Δ AAPS from Baseline Average Peak Pain Responders AAPS Improvement -4.6 85% of patients improved at week 4 100% of patients improved at week 8 *=p<0.05; **=p<0.01 (Evaluable Population with ≥30% change from baseline in AAPS)
Slide 38: Olorinab Ph 2 Trial Evaluating Abdominal Pain in IBS
A Phase 2, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome (IBS) Experiencing Abdominal Pain Primary Endpoint Improvement in the weekly Average Abdominal Pain Scale (AAPS) from baseline to week 12 Study
Slide 39: APD418 for Decompensated Heart Failure (DHF)
APD418 Potential First-in-Class Investigational Beta-3 AdrR Antagonist and Cardiac Myotrope for Decompensated Heart Failure (DHF) January 2020 •
Slide 40: Significant Unmet Need in DHF
Significant Unmet Need in DHF Sources: 1. Heart Failure. Disease Landscape & Forecast. DRG. June 2018.; 2. Dharmarajan K, et al. BMJ. 2015 Feb 5;350:h411.; 3. Nielsen DV, et al. Anesthesiology. 2014 May;120(5):1098-108. Long-Awaited Innovative Approach to DHF 9.5M AHF hospitalizations in 20251 No ap
Slide 41: APD418 First-in-Class for DHF with Novel MOA
APD418 First-in-Class for DHF with Novel MOA & Improved Cardiac Function Without Hemodynamic Liability Sources: 1. Heart Failure. Disease Landscape & Forecast. DRG. June 2018.; 2. Dharmarajan K, et al. BMJ. 2015 Feb 5;350:h411.; 3. Nielsen DV, et al. Anesthesiology. 2014 May;120(5):1098-108. Canine
Slide 42: APD418 and Cimlanod
APD418 and Cimlanod Sources: 1. Tita C et al. A phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and hemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction. Eur J Heart Fail 2017; 19:1321-1332.; 2. Felker M et al. Rati
Slide 43: Deep Pipeline with Therapeutic Focus
Deep Pipeline with Therapeutic Focus Pipeline of Potential First-in-Class and Best-in-Disease Assets Internal Programs: Early Research Pre-clin. Phase 1 Phase 2 Phase 3 Etrasimod GI ELEVATE UC 52 ELEVATE UC 12 Crohn’s Disease (CD) Eosinophilic Esophagitis (EoE) Derm ADVISE (Atopic Dermatitis) Alopec
Slide 44: Arena Pharmaceuticals
ARENA PHARMACEUTICALS Nasdaq: ARNA
Arena Pharmaceuticals — Investor Presentation (January 2020) on 6ix